TSC22D2 identified as a candidate susceptibility gene of multi-cancer pedigree using genome-wide linkage analysis and whole-exome sequencing

Xiao, Lan; Fang, Wei; Fang, Liang; Li, Qiao; Deng, Hao; Tan, Shiming; Chen, Shuai; Xiong, Fang; Guo, Can; Liao, Qianjin; Li, Xiayu; Zhang, Wenling; Wu, Minghua; Zhou, Yanhong; Xiang, Bo; Zhou, Ming; Li, Xiaoling; Xiong, Wei; Zeng, Zhaoyang; Li, Guiyuan

doi:10.1093/carcin/bgz095

Cited by 34 publications

(27 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The sequences containing the putative miR‐1237‐3p and human PNN mRNA binding sites were amplified and cloned into the pMIR‐REPORT vector, and the sequences are shown in Table . Relative luciferase activity was measured by the Dual‐Luciferase Reporter Assay System (Promega, Madison, WI, USA) using SpectraMax ® iD3 microplate reader (Shanghai, China) (Xiao et al ., 2019).…”

Section: Methodsmentioning

confidence: 99%

LncRNA AATBC regulates Pinin to promote metastasis in nasopharyngeal carcinoma

et al. 2020

Self Cite

View full text Add to dashboard Cite

Long noncoding RNA (lncRNA) have emerged as crucial regulators for a myriad of biological processes, and perturbations in their cellular expression levels have often been associated with cancer pathogenesis. In this study, we identified AATBC (apoptosis‐associated transcript in bladder cancer, LOC284837) as a novel lncRNA. AATBC was found to be highly expressed in nasopharyngeal carcinoma (NPC), and increased AATBC expression was associated with poor survival in patients with NPC. Furthermore, AATBC promoted migration and invasion of NPC cells in vitro, as well as metastasis in vivo. AATBC upregulated the expression of the desmosome‐associated protein pinin (PNN) through miR‐1237‐3p sponging. In turn, PNN interacted with the epithelial–mesenchymal transition (EMT) activator ZEB1 and upregulated ZEB1 expression to promote EMT in NPC cells. Collectively, our results indicate that AATBC promotes NPC progression through the miR‐1237‐3p–PNN–ZEB1 axis. Our findings indicate AATBC as a potential prognostic biomarker or therapeutic target in NPC.

show abstract

Section: Methodsmentioning

confidence: 99%

LncRNA AATBC regulates Pinin to promote metastasis in nasopharyngeal carcinoma

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Malignant cell proliferation is one of the hallmarks of tumor cells [82][83][84][85][86]. Research has shown that c-Myc can promote the transcription of positive cell cycle regulatory factors, such as E2F transcription factors, cyclin D1, and cyclin-dependent kinase 4 (CDK4).…”

Section: Pvt1 Participates In the Proliferation-related Signaling Patmentioning

confidence: 99%

Long non-coding RNA PVT1 interacts with MYC and its downstream molecules to synergistically promote tumorigenesis

Jin

Wang

Zhang

et al. 2019

Cell. Mol. Life Sci.

Self Cite

117

View full text Add to dashboard Cite

Numerous studies have shown that non-coding RNAs play crucial roles in the development and progression of various tumor cells. Plasmacytoma variant translocation 1 (PVT1) mainly encodes a long non-coding RNA (lncRNA) and is located on chromosome 8q24.21, which constitutes a fragile site for genetic aberrations. PVT1 is well-known for its interaction with its neighbor MYC, which is a qualified oncogene that plays a vital role in tumorigenesis. In the past several decades, increasing attention has been paid to the interaction mechanism between PVT1 and MYC, which will benefit the clinical treatment and prognosis of patients. In this review, we summarize the coamplification of PVT1 and MYC in cancer, the positive feedback mechanism, and the latest promoter competition mechanism of PVT1 and MYC, as well as how PVT1 participates in the downstream signaling pathway of c-Myc by regulating key molecules. We also briefly describe the treatment prospects and research directions of PVT1 and MYC.

show abstract

“…BRAF gene mutations are associated with the development of a variety of tumors, such as melanoma [5], lung cancer [6], colorectal cancer [7] and thyroid cancer. In recent years, a large body of literature has shown that the BRAF V600E mutation is associated with a series of adverse clinical pathological factors in PTC, such as advanced disease, invasive characteristics, and others [8][9][10][11][12][13][14]. Many studies have shown that the BRAF V600E mutation may result in the activation of downstream genes of the MAPK pathway, which may lead to a slight downregulation of the sodium iodide symporter (NIS), thereby causing an inaccurate NIS localization wherein the NIS cannot be accurately localized to the cell membrane [15,16].…”

Section: Introductionmentioning

confidence: 99%

The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer

Wang

et al. 2020

J. Cancer

Self Cite

View full text Add to dashboard Cite

Objective: To investigate the correlation between the BRAF V600E gene mutation and clinicopathological features and thyroid function after iodine-131 treatment in patients with papillary thyroid cancer (PTC). Methods: A total of 128 PTC patients who underwent iodine-131 treatment after a total thyroidectomy from February 2015 to November 2016 at Hunan Cancer Hospital, China, were recruited. There were 25 males and 103 females. The age range was 11 to 73 years old. The BRAF V600E mutation in tumor tissues was detected by amplification-restriction mutation system polymerase chain reaction (ARMS-PCR), and the serum levels of Tg, TSH, Tg-Ab, and Tpo-Ab were measured by chemiluminescence after iodine-131 treatment. The BRAF V600E mutation was shown to be associated with clinicopathological characteristics and thyroid function indicators after iodine-131 treatment. Results: BRAF V600E mutation was detected in 75 of the 128 patients (58.6%) and was observed more frequently in cases with elevated Tg levels (Tg>1.00) at 3, 6, 12, and 18 months after treatment compared with patients without any BRAF mutations (P<0.05). Patients with BRAF V600E mutation had significant lower level of Tg-Ab at 3 and 12 months after treatment with iodine-131 than patients without BRAF V600E mutation (P<0.05). Among the 75 BRAF V600E patients, no significant association was found between the levels of TSH and Tpo-Ab after iodine-131 treatment (P>0.05). The BRAF V600E mutation was closely associated with the high-risk and age of the patient (≥45 years old) (P<0.05), but there was no significant correlation with gender, clinical stage, and distant metastasis. Conclusion:The BRAF V600E mutation is closely related to serum Tg elevation after treatment with iodine-131 in papillary thyroid cancer. These findings suggest that this BRAF mutation may be a predictor of the efficacy of iodine-131 treatment for papillary thyroid cancer.

show abstract

TSC22D2 identified as a candidate susceptibility gene of multi-cancer pedigree using genome-wide linkage analysis and whole-exome sequencing

Cited by 34 publications

References 49 publications

LncRNA AATBC regulates Pinin to promote metastasis in nasopharyngeal carcinoma

LncRNA AATBC regulates Pinin to promote metastasis in nasopharyngeal carcinoma

Long non-coding RNA PVT1 interacts with MYC and its downstream molecules to synergistically promote tumorigenesis

The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer

Contact Info

Product

Resources

About